Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apothecon captopril will be sole generic through Feb. 13 after Supreme Court denial of Royce appeal.

Executive Summary

APOTHECON GENERIC CAPTOPRIL EXCLUSIVITY RUNS UNTIL FEB. 13 AFTER SUPREME COURT refused to hear the case of Royce Labs v. Bristol-Myers Squibb Jan. 8. The generic manufacturer was seeking to overturn a Nov. 1 federal appeals court ruling upholding FDA's interpretation of the implementing legislation for the General Agreement on Tariffs & Trade, which granted Bristol six months of additional exclusivity for the ACE inhibitor Capoten, with the new patent term expiring Feb. 13. Bristol's Apothecon generics subsidiary introduced the first generic version of captopril Dec. 1 at a 15% discount to the brand.
UsernamePublicRestriction

Register

PS027470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel